Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | CETP | P11597 | 3/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839007 | 0.90 | TSHR (0.53) | TSHRFOLH1CETPKEAP1FFAR1 | |
| SCHEMBL31308108 | 0.88 | CETP (0.55) | TSHRFOLH1CETPKEAP1FFAR1 | |
| SCHEMBL30887317 | 0.87 | CETP (0.57) | TSHRFOLH1CETPKEAP1FFAR1 | |
| SCHEMBL23710533 | 0.83 | FOLH1 (0.54) | TSHRFOLH1CETPKEAP1FFAR1 | |
| SCHEMBL7860305 | 0.82 | FOLH1 (0.67) | TSHRFOLH1CETP | |
| SCHEMBL5028595 | 0.81 | TSHR (0.60) | TSHRCETPALDH1A1 | |
| SCHEMBL413304 | 0.81 | TSHR (0.60) | TSHRFOLH1CETPMAPK1SLC6A3 | |
| SCHEMBL23710506 | 0.80 | CETP (0.54) | TSHRFOLH1CETPKEAP1FFAR1 | |
| SCHEMBL21811949 | 0.80 | LMNA (0.56) | TSHRHDAC3MAPK1HDAC4HDAC1 | |
| SCHEMBL7301581 | 0.79 | TSHR (0.57) | TSHRCETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | MERCK SHARP & DOHME LLC (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2023177976-A2 | NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF | PROMEGA CORPORATION (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-116601307-A | Nucleic acid modification reagent and use thereof | 普罗美加公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-115385875-A | Taxol derivative and preparation method and application thereof | 中国药科大学 | 2022-11-25 | — | — | CN | disclosed |
| US-20220064710-A1 | NUCLEIC ACID MODIFYING REAGENTS AND USES THEREOF | PROMEGA CORPORATION | 2022-03-03 | — | — | US | disclosed |
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2012-12-06 | — | — | US | disclosed |
| EP-1633362-B1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC (US) | 2012-09-26 | — | — | EP | disclosed |
| US-8129382-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20100256095-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | EISAI INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7750008-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-12-03 | — | — | US | disclosed |
| US-7601719-B2 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | EISAI CORPORATION OF NORTH AMERICA (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | MGI GP, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| US-7456178-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1633362-A4 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP INC (US) | 2008-08-27 | — | — | EP | disclosed |
| US-20080058325-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-7268138-B2 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | MGI GP, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1633362-A2 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | MGI GP, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050020595-A1 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | EISAI INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004105700-A2 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | GUILDFORD PHARMACEUTICALS, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298837-A1 | poly(ADP-ribose) polymerase (PARP) inhibitors such as 9-[(Hydrozinooxy)carbonyl]-2,7-dihydro-6-methoxy 3H-pyrido-[4,3,2-de]phthalazin-3-one, used for treating neuron tissue damage resulting from ischemia and reperfusion injury, depression, inflammatory bowel disorders, arthritis, gout, pain and sepsis | PARP1, PARP2, NLRP3 | TSHR 4438/4885FOLH1 305/4885CETP 4662/4885 |
| US-20080058325-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | TSHR 4816/4885FOLH1 1814/4885CETP 1567/4885 |
| US-20050020595-A1 | Compounds, methods and pharmaceutical compositions for inhibiting PARP | PARP1, PARP2, PARP3 | TSHR 4812/4885FOLH1 1788/4885CETP 1494/4885 |
| US-20240067657-A1 | AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES | TLR7, MALT1, PNPO | TSHR 1647/4885FOLH1 2589/4885CETP 2876/4885 |
| US-20120309717-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | TSHR 4812/4885FOLH1 1788/4885CETP 1494/4885 |
| US-20090088407-A1 | Administering temozolomide; poly/adp-ribose/polymerase (PARP) inhibitors; melanoma, lymphoma, glioblastoma multiforme | PARP1, PARP2, PARP11 | TSHR 4277/4885FOLH1 2443/4885CETP 3748/4885 |
| US-20100256095-A1 | COMPOUNDS, METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PARP | PARP1, PARP2, PARP3 | TSHR 4812/4885FOLH1 1788/4885CETP 1494/4885 |
| US-20220064710-A1 | NUCLEIC ACID MODIFYING REAGENTS AND USES THEREOF | POLRMT, NSUN2, ADAR | TSHR 3056/4885FOLH1 942/4885CETP 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.